Your email has been successfully added to our mailing list.

×
0 -0.00502092050209209 -0.00920502092050219 -0.0133891213389121 0.0158995815899581 0.0276150627615063 0.0167364016736401 0.0284518828451883
Stock impact report

FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S. [Seeking Alpha]

Nurix Therapeutics, Inc. - Common stock (NRIX) 
Company Research Source: Seeking Alpha
FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.Jun. 30, 2022 9:12 AM ETNurix Therapeutics, Inc. ()By:Anuron MitraSA News EditorJHVEPhoto/iStock Editorial via Getty Images"We look forward to sharing initial biomarker data from the Phase 1 trial at an appropriate medical meeting in the second half of 2022,� 's executive VP of clinical development Robert Brown. Show less Read more
Impact Snapshot
Event Time:
NRIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for NRIX alerts
Opt-in for
NRIX alerts

from News Quantified
Opt-in for
NRIX alerts

from News Quantified